These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22530575)

  • 1. Management of bleeding disorders in children.
    Berntorp E; Halimeh S; Gringeri A; Mathias M; Escuriola C; Pérez R
    Haemophilia; 2012 May; 18 Suppl 2():15-23. PubMed ID: 22530575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of bleeding disorders in adults.
    Peyvandi F; Klamroth R; Carcao M; Federici AB; DI Minno G; Jiménez-Yuste V; Rodriguez Merchán EC
    Haemophilia; 2012 May; 18 Suppl 2():24-36. PubMed ID: 22530576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
    Mancuso ME; Graca L; Auerswald G; Santagostino E
    Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric hemophilia: a review.
    Kulkarni R; Soucie JM
    Semin Thromb Hemost; 2011 Oct; 37(7):737-44. PubMed ID: 22187396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
    Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
    Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difficult clinical challenges in haemophilia: international experiential perspectives.
    Forsyth AL; Giangrande P; Hay CR; Kenet G; Kessler CM; Knöbl PN; Llinás A; Santagostino E; Young G
    Haemophilia; 2012 Jul; 18 Suppl 5():39-45. PubMed ID: 22757683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
    Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
    Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
    [No Abstract]   [Full Text] [Related]  

  • 9. [Early prophylaxis of bleeding in haemophilia and a risk of inhibitor development].
    Ociepa T; Urasiński T
    Pol Merkur Lekarski; 2011 Mar; 30(177):215-8. PubMed ID: 21545001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological aspects of inhibitor development.
    Reding MT
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment related factors and inhibitor development in children with severe haemophilia A.
    Maclean PS; Richards M; Williams M; Collins P; Liesner R; Keeling DM; Yee T; Will AM; Young D; Chalmers EA;
    Haemophilia; 2011 Mar; 17(2):282-7. PubMed ID: 21070501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade.
    Mannucci PM
    Haemophilia; 2012 May; 18 Suppl 2():2-7. PubMed ID: 22530573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of current knowledge to the management of bleeding events during immune tolerance induction.
    Di Paola J; Aledort L; Britton H; Carcao M; Grabowski E; Hutter J; Journeycake J; Kempton C; Leissinger C
    Haemophilia; 2006 Nov; 12(6):591-7. PubMed ID: 17083508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
    Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.
    DiMichele DM
    Haemophilia; 2006 Dec; 12 Suppl 6():37-41; discussion 41-2. PubMed ID: 17123392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
    Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.